El Salvador vs Guyana: Access to anti-retroviral drugs, female
El Salvador
74.0%
in 2024
Guyana
75.0%
in 2024
El Salvador rank
69th
Guyana rank
67th
Access to anti-retroviral drugs, female over time
- El Salvador
- Guyana
How they compare
Guyana currently reports 75.0% against 74.0% in El Salvador, a difference of 1.0%.
The two have swapped places 8 times across 25 shared years of data; in 2000 it was Guyana ahead.
El Salvador ranks 69th and Guyana ranks 67th of 141 countries.
Across the 3 decades both report, El Salvador averaged higher in 1 and Guyana in 2.
Head to head by decade
| Decade | El Salvador | Guyana | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 11.9% | 20.9% | 9.0% | Guyana |
| 2010s | 64.3% | 66.6% | 2.3% | Guyana |
| 2020s | 74.2% | 72.6% | 1.6% | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, El Salvador or Guyana?
- Guyana, at 75.0% against 74.0% in El Salvador as of 2024.
- What is the difference in access to anti-retroviral drugs, female between El Salvador and Guyana?
- 1.0%, with Guyana ahead.
- How many years of comparable data are there for El Salvador and Guyana?
- 25 years are reported by both, from 2000 to 2024.
- How do El Salvador and Guyana rank globally for access to anti-retroviral drugs, female?
- El Salvador ranks 69th and Guyana ranks 67th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.